| Year |
Citation |
Score |
| 2023 |
Mishra DK, Popovski D, Morris SM, Bondoc A, Senthil Kumar S, Girard EJ, Rutka J, Fouladi M, Huang A, Olson JM, Drissi R. Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward. Neuro-Oncology. PMID 37713135 DOI: 10.1093/neuonc/noad170 |
0.338 |
|
| 2023 |
Noll A, Myers C, Biery MC, Meechan M, Tahiri S, Rajendran A, Berens ME, Paine D, Byron S, Zhang J, Winter C, Pakiam F, Leary SES, Cole BL, Jackson ER, ... Olson JM, et al. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma. Neoplasia (New York, N.Y.). 43: 100921. PMID 37603953 DOI: 10.1016/j.neo.2023.100921 |
0.336 |
|
| 2021 |
Leary SES, Lindsay K, Geyer JR, Mehmet K, Huang J, Smith KS, Hadley J, Ermoian R, MacDonald TJ, Goldman S, Phillips P, Young Poussaint T, Olson JM, Ellison DW, Dunkel IJ, et al. Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology. PMID 34935967 DOI: 10.1093/neuonc/noab293 |
0.311 |
|
| 2021 |
Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM. Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival. Journal of Neuro-Oncology. PMID 33963961 DOI: 10.1007/s11060-021-03767-x |
0.31 |
|
| 2021 |
Skowron P, Farooq H, Cavalli FMG, Morrissy AS, Ly M, Hendrikse LD, Wang EY, Djambazian H, Zhu H, Mungall KL, Trinh QM, Zheng T, Dai S, Stucklin ASG, Vladoiu MC, ... Olson JM, et al. The transcriptional landscape of Shh medulloblastoma. Nature Communications. 12: 1749. PMID 33741928 DOI: 10.1038/s41467-021-21883-0 |
0.33 |
|
| 2020 |
Rusert JM, Juarez EF, Brabetz S, Jensen J, Garancher A, Chau LQ, Tacheva-Grigorova SK, Wahab S, Udaka YT, Finlay D, Seker-Cin H, Reardon B, Gröbner S, Serrano J, Ecker J, ... Olson JM, et al. Functional precision medicine identifies new therapeutic candidates for medulloblastoma. Cancer Research. PMID 33046443 DOI: 10.1158/0008-5472.CAN-20-1655 |
0.301 |
|
| 2020 |
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, ... Olson JM, et al. Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nature Neuroscience. PMID 32424282 DOI: 10.1038/S41593-020-0628-4 |
0.409 |
|
| 2020 |
Crook ZR, Girard E, Sevilla GP, Merrill M, Friend D, Rupert PB, Pakiam F, Nguyen E, Yin C, Ruff RO, Hopping G, Strand AD, Finton KAK, Coxon M, Mhyre AJ, ... Olson JM, et al. A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules. Journal of Molecular Biology. PMID 32304700 DOI: 10.1016/J.Jmb.2020.04.002 |
0.302 |
|
| 2020 |
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Morcavallo A, Henderson JJ, ... Olson JM, et al. Abstract IA11: Overcoming immune evasion in pediatric brain tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Ia11 |
0.416 |
|
| 2019 |
Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, Xu L, Zhou W, Zheng T, Luo Z, Berry KP, Pribnow A, Smith SM, Fuller C, Jones BV, ... Olson JM, et al. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. PMID 31474569 DOI: 10.1016/J.Ccell.2019.07.009 |
0.464 |
|
| 2019 |
Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, ... Olson JM, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications. 10: 2400. PMID 31160565 DOI: 10.1038/S41467-019-10307-9 |
0.347 |
|
| 2019 |
Abdelfattah N, Natarajan S, Chen Y, Chow K, Chen S, Olson J, Baskin D, Yun K. PDTM-09. Yap1 FUNCTION IN SEX-BIASED MEDULLOBLASTOMA FORMATION AND ANTI-TUMOR IMMUNITY Neuro-Oncology. 21: vi188-vi188. DOI: 10.1093/Neuonc/Noz175.785 |
0.39 |
|
| 2019 |
Hoellerbauer P, Kufeld M, Arora S, Girard E, Olson J, Biery M, Chambwe N, Paddison P. COMP-04. MODELING PRECISION ONCOLOGY FOR GLIOBLASTOMA THROUGH INTEGRATION OF DESCRIPTIVE, FUNCTIONAL, AND NETWORK-BASED GENOMICS Neuro-Oncology. 21: vi61-vi62. DOI: 10.1093/Neuonc/Noz175.247 |
0.445 |
|
| 2019 |
Crotty E, Brasel K, Pakiam F, Girard E, Olson J. TMIC-48. MACROPHAGE DEPLETION COMBINED WITH RADIATION IN A PRECLINICAL MEDULLOBLASTOMA MODEL Neuro-Oncology. 21: vi258-vi258. DOI: 10.1093/Neuonc/Noz175.1082 |
0.399 |
|
| 2019 |
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, M.G. Cavalli F, Farooq H, Ramaswamy V, J.M. Jones S, Moore RA, ... ... Olson JM, et al. IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA Neuro-Oncology. 21: ii93-ii93. DOI: 10.1093/Neuonc/Noz036.124 |
0.337 |
|
| 2019 |
Pfaff E, Aichmüller C, Sill M, Stichel D, Snuderl M, Karajannis MA, Schuhmann MU, Schittenhelm J, Hasselblatt M, Thomas C, Korshunov A, Rhizova M, Temming P, Orr BA, Ellison DW, ... Olson JM, et al. GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS Neuro-Oncology. 21: ii81-ii82. DOI: 10.1093/Neuonc/Noz036.077 |
0.355 |
|
| 2018 |
Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Şeker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, Mack NL, Pakiam F, Schwalm B, Korshunov A, Balasubramanian GP, ... Olson JM, et al. A biobank of patient-derived pediatric brain tumor models. Nature Medicine. PMID 30349086 DOI: 10.1038/S41591-018-0207-3 |
0.666 |
|
| 2018 |
Hwang EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Leary S, Zhou T, von Deimling A, ... Olson JM, et al. Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017764720. PMID 30332335 DOI: 10.1200/Jco.2017.76.4720 |
0.34 |
|
| 2018 |
Morris SM, Mhyre AJ, Carmack SS, Myers CH, Burns C, Ye W, Ferrer M, Olson JM, Klinghoffer RA. A modified gene trap approach for improved high-throughput cancer drug discovery. Oncogene. PMID 29717260 DOI: 10.1038/S41388-018-0274-4 |
0.37 |
|
| 2018 |
Sottero TL, Girard EJ, Myers C, Hopping G, Mhyre AJ, Olson JM. Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging. Anticancer Research. 38: 51-60. PMID 29277756 DOI: 10.21873/Anticanres.12191 |
0.374 |
|
| 2018 |
Hoellerbauer P, Arora S, Kufeld M, Carter L, Girard EJ, Feldman H, Corrin P, Olson JM, Paddison PJ. Abstract 413: Emerging principles in synthetic lethality in glioblastoma Cancer Research. 78: 413-413. DOI: 10.1158/1538-7445.Am2018-413 |
0.412 |
|
| 2018 |
Brabetz S, Groebner SN, Jaeger N, Milde T, Ecker J, Selt F, Witt O, Rusert JM, Koster J, Leary SE, Li X, Wechsler-Reya RJ, Olson JM, Pfister SM, Kool M. PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH Neuro-Oncology. 20: i155-i155. DOI: 10.1093/Neuonc/Noy059.574 |
0.4 |
|
| 2018 |
Strand A, Cole B, Leary S, Olson J. PCLN-04. BRAIN TUMOR PATIENT DERIVED ORTHOTOPIC XENOGRAFTS INDUCE TUMORS OF MOUSE ORIGIN Neuro-Oncology. 20: i155-i155. DOI: 10.1093/Neuonc/Noy059.573 |
0.439 |
|
| 2017 |
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, ... Olson JM, et al. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research. 77: e62-e66. PMID 29092942 DOI: 10.1158/0008-5472.Can-17-0582 |
0.41 |
|
| 2017 |
Cook Sangar ML, Genovesi LA, Nakamoto MW, Davis MJ, Knoblaugh SE, Ji P, Millar A, Wainwright B, Olson JM. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28637687 DOI: 10.1158/1078-0432.Ccr-16-2943 |
0.45 |
|
| 2017 |
Ding Y, Herman JA, Toledo CM, Lang JM, Corrin P, Girard EJ, Basom R, Delrow JJ, Olson JM, Paddison PJ. ZNF131 suppresses centrosome fragmentation in glioblastoma stem-like cells through regulation of HAUS5. Oncotarget. PMID 28596487 DOI: 10.18632/Oncotarget.18153 |
0.4 |
|
| 2017 |
Frazier J, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, Tretyak I, Ditzler S, Tripp CD, Choy K, Gillings S, ... Olson JM, et al. Multi-drug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Research. PMID 28364003 DOI: 10.1158/0008-5472.Can-17-0084 |
0.438 |
|
| 2017 |
Xu T, Zhang H, Park SS, Venneti S, Kuick R, Ha K, Michael LE, Santi M, Uchida C, Uchida T, Srinivasan A, Olson JM, Dlugosz AA, Camelo-Piragua S, Rual JF. Loss of Pin1 Suppresses Hedgehog-Driven Medulloblastoma Tumorigenesis. Neoplasia (New York, N.Y.). 19: 216-225. PMID 28167297 DOI: 10.1016/J.Neo.2017.01.002 |
0.443 |
|
| 2017 |
Hoellerbauer P, Feldman H, Arora S, Carter L, Girard EJ, Corrin P, Olson JM, Holland EC, Paddison PJ. Abstract B14: Precision functional genomics for glioblastoma: Identifying molecular therapeutic targets using CRISPR-Cas9 and RNAi technologies in patient isolates Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B14 |
0.403 |
|
| 2017 |
Crook ZR, Bradley P, Sevilla G, Friend D, King C, Mhyre A, Strong R, Baker D, Olson JM. Abstract 5573: A high-affinity Optide (optimized peptide) inhibitor of the Hippo pathway’s YAP-TEAD interaction Cancer Research. 77: 5573-5573. DOI: 10.1158/1538-7445.Am2017-5573 |
0.365 |
|
| 2017 |
Sottero TL, Girard EJ, Myers CH, Olson JM. Abstract 5141: Optimizing peptide-drug conjugate delivery as an alternative to antibody-drug conjugates for solid tumors Cancer Research. 77: 5141-5141. DOI: 10.1158/1538-7445.Am2017-5141 |
0.413 |
|
| 2017 |
Mhyre AJ, Turnbaugh S, Morris SM, Xin H, Paddison PJ, Ferrer M, Olson JM. Abstract 3200: Targeting PHF5A for the treatment of glioblastoma and other Myc-driven cancers Cancer Research. 77: 3200-3200. DOI: 10.1158/1538-7445.Am2017-3200 |
0.393 |
|
| 2017 |
Brabetz S, Gröbner SN, Seker-Cin H, Selt F, Milde T, Jones DT, Wise MT, Rusert JM, Pedro K, Strand A, Witt O, Leary SE, Li X, Wechsler-Reya RJ, Olson JM, et al. Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors Cancer Research. 77: 1935-1935. DOI: 10.1158/1538-7445.Am2017-1935 |
0.418 |
|
| 2017 |
Hwang E, Kool M, Burger P, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Zhou T, Leary S, Heideman N, ... ... Olson J, et al. PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL Neuro-Oncology. 19: vi184-vi185. DOI: 10.1093/Neuonc/Nox168.749 |
0.368 |
|
| 2017 |
Lee A, Cole B, Poliachik S, Ojemann J, Miller D, Novak J, Hansen S, Olson J, Leary S. TRTH-12. PHASE 1 SAFETY, PHARMACOKINETIC AND IMAGING STUDY OF BLZ-100 TUMOR PAINT IN PEDIATRIC BRAIN TUMOR PATIENTS Neuro-Oncology. 19: iv54-iv54. DOI: 10.1093/Neuonc/Nox083.224 |
0.39 |
|
| 2017 |
Brabetz S, Schmidt C, Groebner SN, Mack N, Seker-Cin H, Jones DT, Chavez L, Milde T, Witt O, Leary SE, Li X, Wechsler-Reya RJ, Olson JM, Pfister SM, Kool M. TMOD-05. MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS AND THEIR USE IN PRECLINICAL EXPERIMENTS Neuro-Oncology. 19: iv49-iv49. DOI: 10.1093/Neuonc/Nox083.204 |
0.415 |
|
| 2017 |
Wang A, Abecassis I, Wang S, Jones D, Cole B, Leary S, Lockwood C, Ene C, Fallah A, Olson J, Ellenbogen R, Holland E, Ojemann J. Primitive Desmoplastic Neuroepithelial Tumor of the Skull Base Journal of Neurological Surgery Part B: Skull Base. 78: S1-S156. DOI: 10.1055/S-0037-1600828 |
0.395 |
|
| 2016 |
Moreno-Gonzalez A, Olson JM, Klinghoffer RA. Predicting responses to chemotherapy in the context that matters - the patient. Molecular & Cellular Oncology. 3: e1057315. PMID 27308571 DOI: 10.1080/23723556.2015.1057315 |
0.409 |
|
| 2016 |
Pei Y, Liu KW, Wang J, Garancher A, Tao R, Esparza LA, Maier DL, Udaka YT, Murad N, Morrissy S, Seker-Cin H, Brabetz S, Qi L, Kogiso M, Schubert S, Olson JM, et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Cancer Cell. 29: 311-323. PMID 26977882 DOI: 10.1016/J.Ccell.2016.02.011 |
0.457 |
|
| 2016 |
Rusert JM, Garancher A, Udaka YT, Brabetz S, Esparza LA, Seker-Cin H, Qi L, Kogiso M, Schubert S, Milde T, Cho Y, Li X, Olson JM, Crawford JR, Levy ML, et al. Abstract B37: Chemi-genomic analysis of patient-derived xenografts to identify personalized therapies for medulloblastoma Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B37 |
0.41 |
|
| 2016 |
Brabetz S, Seker-Cin H, Gröbner SN, Mack NL, Hovestadt V, Jones DTW, Milde T, Wise MT, Rusert JM, Pedro K, Bloom K, Li X, Wechsler-Reya RJ, Olson JM, Pfister SM, et al. Abstract A07: Molecular characterization of patient-derived xenograft models of pediatric brain tumors Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A07 |
0.482 |
|
| 2016 |
Herman JA, Paddison PJ, DeLuca J, Olson J. Abstract B27: Kinetochore-microtubule attachments as a precision therapy target Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-B27 |
0.437 |
|
| 2016 |
Olson J. Abstract SY43-02: Predicting solid tumor sensitivity to drug combinations using a multiplexed microinjection platform and prioritizing therapies for clinical development Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Sy43-02 |
0.452 |
|
| 2016 |
Sottero T, Girard EJ, Correnti C, Stroud MR, Kier BL, Mhyre AJ, Olson J. Abstract LB-231: An optide (optimized knottin-peptide) that inhibits tumor cell growth In vitro and accumulates in sarcoma flank tumors in vivo Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-231 |
0.415 |
|
| 2016 |
Toledo C, Yu D, Hoellerbauer P, Davis R, Basom R, Girard E, Corrin P, Bolouri H, Davison J, Zhang Q, Nam D, Lee J, Pollard S, Delrow J, Clurman B, ... Olson J, et al. Abstract 4370: Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in patient-derived glioblastoma stem-like cells Cancer Research. 76: 4370-4370. DOI: 10.1158/1538-7445.Am2016-4370 |
0.408 |
|
| 2016 |
Crook ZR, Bradley P, King C, Mhyre AJ, Baker D, Olson JM. Abstract 2971: Optides (optimized knottin peptides) computationally designed to target the oncogenic HIPPO pathway Cancer Research. 76: 2971-2971. DOI: 10.1158/1538-7445.Am2016-2971 |
0.376 |
|
| 2016 |
Brabetz S, Groebner SN, Seker-Cin H, Mack NL, Hovestadt V, Jones DTW, Selt F, Milde T, Wise MT, Rusert JM, Pedro K, Bloom K, Witt O, Leary SE, Li X, ... ... Olson JM, et al. PCM-16MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS Neuro-Oncology. 18: iii142.3-iii142. DOI: 10.1093/Neuonc/Now080.16 |
0.48 |
|
| 2015 |
Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Hart T, Bolouri H, Davison J, Zhang Q, Hardcastle J, Aronow BJ, Plaisier CL, ... Olson JM, et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Reports. PMID 26673326 DOI: 10.1016/J.Celrep.2015.11.021 |
0.369 |
|
| 2015 |
Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, Kooperberg C, Olson JM, Cattaneo E. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Human Molecular Genetics. PMID 26577153 DOI: 10.1093/Hmg/Ddv416 |
0.337 |
|
| 2015 |
Fidel J, Kennedy KC, Dernell WS, Hansen S, Wiss V, Stroud MR, Molho JI, Knoblaugh SE, Meganck J, Olson JM, Rice B, Parrish-Novak J. Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors. Cancer Research. 75: 4283-91. PMID 26471914 DOI: 10.1158/0008-5472.Can-15-0471 |
0.386 |
|
| 2015 |
Parrish-Novak J, Holland EC, Olson JM. Image-Guided Tumor Resection. Cancer Journal (Sudbury, Mass.). 21: 206-12. PMID 26049700 DOI: 10.1097/Ppo.0000000000000113 |
0.346 |
|
| 2015 |
Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Child's Nervous System : Chns : Official Journal of the International Society For Pediatric Neurosurgery. 31: 1283-9. PMID 25930724 DOI: 10.1007/S00381-015-2725-3 |
0.352 |
|
| 2015 |
Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, ... Olson JM, et al. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Science Translational Medicine. 7: 284ra58. PMID 25904742 DOI: 10.1126/Scitranslmed.Aaa7489 |
0.79 |
|
| 2015 |
Girard E, Ditzler S, Lee D, Richards A, Yagle K, Park J, Eslamy H, Bobilev D, Vrignaud P, Olson J. Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro-Oncology. 17: 107-15. PMID 25140037 DOI: 10.1093/Neuonc/Nou163 |
0.382 |
|
| 2015 |
Herman JA, Toledo CM, Olson JM, DeLuca JG, Paddison PJ. Molecular pathways: regulation and targeting of kinetochore-microtubule attachment in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 233-9. PMID 25104085 DOI: 10.1158/1078-0432.Ccr-13-0645 |
0.312 |
|
| 2015 |
Olson JM, Strong R, Mehlin C, Correnti C. Abstract 2443: Optides (optimized peptides), a new knottin-based cancer drug discovery platform Cancer Research. 75: 2443-2443. DOI: 10.1158/1538-7445.Am2015-2443 |
0.332 |
|
| 2015 |
Ding Y, Toledo C, Hoellerbauer P, Basom R, Girad E, Lee E, Corrin P, Lin Q, Li X, Nam D, Lee J, Zhu J, Pollard S, Delrow J, Olson J, et al. Abstract 1106: Genome-wide CRISPR-Cas9 screens reveal candidate therapeutic targets and tumor suppressor genes for human glioma Cancer Research. 75: 1106-1106. DOI: 10.1158/1538-7445.Am2015-1106 |
0.483 |
|
| 2015 |
Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Bolouri H, Davison J, Zhang Q, Nam D, Lee J, Pollard SM, Zhu J, ... ... Olson JM, et al. Abstract C159: Genome-wide CRISPR-Cas9 screens uncover therapeutic targets and tumor suppressor genes in glioblastoma multiforme Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C159 |
0.475 |
|
| 2015 |
Toledo C, Ding Y, Hoellerbauer P, Davis R, Basom R, Girard E, Corrin P, Delrow J, Clurman B, Olson J, Paddison P. ATPS-60COMPREHENSIVE IDENTIFICATION OF GLIOBLASTOMA MULTIFORME THERAPEUTIC TARGETS AND GROWTH SUPPRESSOR GENES USING GENE EDITING Neuro-Oncology. 17: v31.3-v31. DOI: 10.1093/Neuonc/Nov204.60 |
0.401 |
|
| 2015 |
Brabetz S, Seker-Cin H, Grobner SN, Hovestadt V, Jones DTW, Northcott PA, Milde T, Rusert JM, Pedro K, Bloom K, Li X, Wechsler-Reya RJ, Olson JM, Pfister SM, Kool M. PM-09 * ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS Neuro-Oncology. 17: iii33-iii33. DOI: 10.1093/Neuonc/Nov061.131 |
0.489 |
|
| 2015 |
Leary S, Kilburn L, Geyer JR, Olson JM, MacDonald T, Ellison D, Kocak M, Onar A, Ermoian R, Poussaint TY, Boyett JM, Kun L, Fouladi M. MB-32 * FEASIBILITY OF VORINOSTAT COMBINED WITH ISOTRETINOIN AND CHEMOTHERAPY FOR YOUNG CHILDREN WITH NEWLY DIAGNOSED EMBRYONAL BRAIN TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY Neuro-Oncology. 17: iii27-iii27. DOI: 10.1093/Neuonc/Nov061.108 |
0.348 |
|
| 2014 |
Kumar A, Boyle EA, Tokita M, Mikheev AM, Sanger MC, Girard E, Silber JR, Gonzalez-Cuyar LF, Hiatt JB, Adey A, Lee C, Kitzman JO, Born DE, Silbergeld DL, Olson JM, et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biology. 15: 530. PMID 25608559 DOI: 10.1186/S13059-014-0530-Z |
0.39 |
|
| 2014 |
Lindsey JC, Kawauchi D, Schwalbe EC, Solecki DJ, Selby MP, McKinnon PJ, Olson JM, Hayden JT, Grundy RG, Ellison DW, Williamson D, Bailey S, Roussel MF, Clifford SC. Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance. Oncogene. PMID 25531316 DOI: 10.1038/Onc.2014.405 |
0.417 |
|
| 2014 |
Morfouace M, Shelat A, Jacus M, Freeman BB, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 25: 516-29. PMID 24684846 DOI: 10.1016/J.Ccr.2014.02.009 |
0.31 |
|
| 2014 |
Toledo CM, Herman JA, Olsen JB, Ding Y, Corrin P, Girard EJ, Olson JM, Emili A, DeLuca JG, Paddison PJ. BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Developmental Cell. 28: 282-94. PMID 24462187 DOI: 10.1016/J.Devcel.2013.12.014 |
0.323 |
|
| 2014 |
Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, ... Olson JM, et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica. 127: 189-201. PMID 24264598 DOI: 10.1007/S00401-013-1213-7 |
0.317 |
|
| 2013 |
Akcan M, Stroud MR, Hansen SJ, Clark RJ, Daly NL, Craik DJ, Olson JM. Correction to Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted Therapy Journal of Medicinal Chemistry. 56: 9807-9807. PMID 26339105 DOI: 10.1021/Jm4016119 |
0.325 |
|
| 2013 |
Gershon TR, Crowther AJ, Tikunov A, Garcia I, Annis R, Yuan H, Miller CR, Macdonald J, Olson J, Deshmukh M. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer & Metabolism. 1: 2. PMID 24280485 DOI: 10.1186/2049-3002-1-2 |
0.356 |
|
| 2013 |
Hatton BA, Ellison DW, Gajjar A, Kool M, Fero M, Olson JM. Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma. Biomarker Research. 1: 14. PMID 24252239 DOI: 10.1186/2050-7771-1-14 |
0.788 |
|
| 2013 |
Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1254-60. PMID 24107773 DOI: 10.4161/Epi.26486 |
0.56 |
|
| 2013 |
Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, Wu X, Shih D, Tapscott SJ, LeBlanc M, Taylor MD, Olson JM. MyoD is a tumor suppressor gene in medulloblastoma. Cancer Research. 73: 6828-37. PMID 24092238 DOI: 10.1158/0008-5472.Can-13-0730-T |
0.661 |
|
| 2013 |
Lee SJ, Lindsey S, Graves B, Yoo S, Olson JM, Langhans SA. Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma. Plos One. 8: e71455. PMID 23951168 DOI: 10.1371/Journal.Pone.0071455 |
0.419 |
|
| 2013 |
Hubert CG, Bradley RK, Ding Y, Toledo CM, Herman J, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P, Hardcastle J, Basom R, Delrow JJ, Webb T, Pollard SM, ... Olson JM, et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes & Development. 27: 1032-45. PMID 23651857 DOI: 10.1101/Gad.212548.112 |
0.743 |
|
| 2013 |
Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, Vazquez J, Basom R, Zhang B, Risler JK, Pollard SM, Nam DH, Delrow JJ, Zhu J, Lee J, ... Olson JM, et al. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discovery. 3: 198-211. PMID 23154965 DOI: 10.1158/2159-8290.Cd-12-0353 |
0.737 |
|
| 2013 |
Aref D, Moffatt CJ, Agnihotri S, Ramaswamy V, Dubuc AM, Northcott PA, Taylor MD, Perry A, Olson JM, Eberhart CG, Croul SE. Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. Brain Pathology (Zurich, Switzerland). 23: 178-91. PMID 22966790 DOI: 10.1111/J.1750-3639.2012.00631.X |
0.445 |
|
| 2013 |
Olson JM, Girard E, Ditzler S, Richards A, Lee D, Vrignaud P. Abstract 5055: Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Cancer Research. 73: 5055-5055. DOI: 10.1158/1538-7445.Am2013-5055 |
0.455 |
|
| 2013 |
Hubert CG, Bradley RK, Ding Y, Chad TM, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P, Basom R, Delrow JJ, Webb T, Pollard SM, Lee J, Olson JM, et al. Abstract A20: Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-A20 |
0.738 |
|
| 2013 |
Ding Y, Hubert C, Herman J, DeLuca J, Olson J, Paddison P. Abstract A05: Functional genetic approach identifies cancer-specific requirement for BUB1B/BubR1 in human brain tumor isolates and genetically transformed cells Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-A05 |
0.737 |
|
| 2012 |
Dey J, Ditzler S, Knoblaugh SE, Hatton BA, Schelter JM, Cleary MA, Mecham B, Rorke-Adams LB, Olson JM. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Molecular and Cellular Biology. 32: 4104-15. PMID 22869526 DOI: 10.1128/Mcb.00862-12 |
0.766 |
|
| 2012 |
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, ... Olson JM, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 488: 49-56. PMID 22832581 DOI: 10.1038/Nature11327 |
0.332 |
|
| 2012 |
Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, ... Olson JM, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proceedings of the National Academy of Sciences of the United States of America. 109: 7859-64. PMID 22550175 DOI: 10.1073/Pnas.1114718109 |
0.803 |
|
| 2012 |
Leary SE, Olson JM. The molecular classification of medulloblastoma: driving the next generation clinical trials. Current Opinion in Pediatrics. 24: 33-9. PMID 22189395 DOI: 10.1097/Mop.0B013E32834Ec106 |
0.31 |
|
| 2012 |
Hubert CG, Ding Y, Toledo C, Paddison PJ, Olson JM, Berndt J. Abstract 5118: A functional genetic approach in patient-derived glioblastoma stem cells reveals pre-mRNA splicing components to be cancer-lethal gene targets Cancer Research. 72: 5118-5118. DOI: 10.1158/1538-7445.Am2012-5118 |
0.737 |
|
| 2012 |
Berndt JD, Frazier J, Grenley M, Bahrami B, Moon RT, Olson J, Klinghoffer R. Abstract 5116: Identification and rapidin vivovalidation of a novel drug combination for treating melanoma Cancer Research. 72: 5116-5116. DOI: 10.1158/1538-7445.Am2012-5116 |
0.421 |
|
| 2012 |
Dey J, Tapscott SJ, Olson JM. Abstract 1431: A novel tumor-suppressor role of MyoD, a muscle differentiation factor, in mouse models of medulloblastoma Cancer Research. 72: 1431-1431. DOI: 10.1158/1538-7445.Am2012-1431 |
0.667 |
|
| 2012 |
Leonard A, Wolff J, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Pollack I, Jakacki R, Butterfield L, Okada H, Fangusaro J, Warren KE, Mullins C, Jurgen P, Julia S, ... ... Olson J, et al. HIGH GRADE GLIOMAS Neuro-Oncology. 14: i56-i68. DOI: 10.1093/Neuonc/Nos102 |
0.642 |
|
| 2011 |
Stroud MR, Hansen SJ, Olson JM. In vivo bio-imaging using chlorotoxin-based conjugates. Current Pharmaceutical Design. 17: 4362-71. PMID 22204434 DOI: 10.2174/138161211798999375 |
0.388 |
|
| 2011 |
Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3999-4006. PMID 21931021 DOI: 10.1200/Jco.2011.35.5677 |
0.306 |
|
| 2011 |
Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3529-34. PMID 21825264 DOI: 10.1200/Jco.2011.35.7806 |
0.311 |
|
| 2011 |
Cherry TJ, Wang S, Bormuth I, Schwab M, Olson J, Cepko CL. NeuroD factors regulate cell fate and neurite stratification in the developing retina. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7365-79. PMID 21593321 DOI: 10.1523/Jneurosci.2555-10.2011 |
0.322 |
|
| 2011 |
Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. Bmc Cancer. 11: 144. PMID 21501498 DOI: 10.1186/1471-2407-11-144 |
0.421 |
|
| 2011 |
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1424-30. PMID 21098324 DOI: 10.1200/Jco.2010.28.5148 |
0.343 |
|
| 2011 |
Lindsey JC, Schwalbe EC, Kawauchi D, Olson JM, McKinnon PJ, Gilbertson RJ, Roussel MF, Ellison DW, Bailey S, Clifford SC. Abstract 3449: Epigenomics identifies conserved DNA methylation events associated with medulloblastoma development in humans and mice Cancer Research. 71: 3449-3449. DOI: 10.1158/1538-7445.Am2011-3449 |
0.419 |
|
| 2010 |
Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, Goldstein DR, Spires TL, Pritchard J, Olson JM, van Dellen A, Hannan AJ, Cha JH. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. Journal of Neuropathology and Experimental Neurology. 69: 817-27. PMID 20613636 DOI: 10.1097/Nen.0B013E3181Ea167F |
0.336 |
|
| 2010 |
Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 29: 3865-72. PMID 20440271 DOI: 10.1038/Onc.2010.142 |
0.774 |
|
| 2010 |
Giussani C, Poliakov A, Ferri RT, Plawner LL, Browd SR, Shaw DW, Filardi TZ, Hoeppner C, Geyer JR, Olson JM, Douglas JG, Villavicencio EH, Ellenbogen RG, Ojemann JG. DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. Neuroimage. 52: 217-23. PMID 20363335 DOI: 10.1016/J.Neuroimage.2010.03.079 |
0.346 |
|
| 2010 |
Ravanpay AC, Hansen SJ, Olson JM. Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation. Molecular and Cellular Neurosciences. 44: 178-89. PMID 20346398 DOI: 10.1016/J.Mcn.2010.03.006 |
0.705 |
|
| 2010 |
Lee MJ, Veiseh O, Bhattarai N, Sun C, Hansen SJ, Ditzler S, Knoblaugh S, Lee D, Ellenbogen R, Zhang M, Olson JM. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. Plos One. 5: e9536. PMID 20209054 DOI: 10.1371/Journal.Pone.0009536 |
0.44 |
|
| 2010 |
Fouladi M, Olson J, Stewart CF, Kocak M, Gajjar AJ, Demuth T, Goldman S, Kun LE, Boyett JM, Gilbertson RJ. A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study. Journal of Clinical Oncology. 28: 9502-9502. DOI: 10.1200/Jco.2010.28.15_Suppl.9502 |
0.415 |
|
| 2009 |
Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, Du K, Pullar B, Lee D, Ellenbogen RG, Olson J, Zhang M. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Research. 69: 6200-7. PMID 19638572 DOI: 10.1158/0008-5472.Can-09-1157 |
0.4 |
|
| 2008 |
Sun C, Fang C, Stephen Z, Veiseh O, Hansen S, Lee D, Ellenbogen RG, Olson J, Zhang M. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (London, England). 3: 495-505. PMID 18694312 DOI: 10.2217/17435889.3.4.495 |
0.325 |
|
| 2008 |
Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, Hallahan AR, Olson JM. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Research. 68: 1768-76. PMID 18339857 DOI: 10.1158/0008-5472.Can-07-5092 |
0.798 |
|
| 2008 |
Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small (Weinheim An Der Bergstrasse, Germany). 4: 372-9. PMID 18232053 DOI: 10.1002/Smll.200700784 |
0.404 |
|
| 2008 |
Ravanpay AC, Olson JM. E protein dosage influences brain development more than family member identity. Journal of Neuroscience Research. 86: 1472-81. PMID 18214987 DOI: 10.1002/Jnr.21615 |
0.705 |
|
| 2008 |
Pritchard JI, Olson JM. Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas. Cancer Genetics and Cytogenetics. 180: 47-50. PMID 18068533 DOI: 10.1016/J.Cancergencyto.2007.09.008 |
0.387 |
|
| 2008 |
Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). Journal of Neuro-Oncology. 87: 133-41. PMID 18060600 DOI: 10.1007/S11060-007-9505-1 |
0.326 |
|
| 2007 |
Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11758-68. PMID 17959817 DOI: 10.1523/Jneurosci.2461-07.2007 |
0.361 |
|
| 2007 |
Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, ... Olson JM, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Research. 67: 6882-8. PMID 17638899 DOI: 10.1158/0008-5472.Can-06-3948 |
0.729 |
|
| 2007 |
Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, ... Olson JM, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133 |
0.348 |
|
| 2007 |
Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. Plos Genetics. 3: e82. PMID 17500595 DOI: 10.1371/Journal.Pgen.0030082 |
0.311 |
|
| 2007 |
Strand AD, Aragaki AK, Baquet ZC, Hodges A, Cunningham P, Holmans P, Jones KR, Jones L, Kooperberg C, Olson JM. Conservation of regional gene expression in mouse and human brain. Plos Genetics. 3: e59. PMID 17447843 DOI: 10.1371/Journal.Pgen.0030059 |
0.322 |
|
| 2006 |
Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alborán IM, Olson JM, Eisenman RN. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Research. 66: 8655-61. PMID 16951180 DOI: 10.1158/0008-5472.Can-06-1621 |
0.766 |
|
| 2006 |
Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. Journal of Neuro-Oncology. 79: 259-70. PMID 16645722 DOI: 10.1007/S11060-006-9142-0 |
0.772 |
|
| 2006 |
Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, ... Olson JM, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics. 15: 965-77. PMID 16467349 DOI: 10.1093/Hmg/Ddl013 |
0.309 |
|
| 2006 |
Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Human Molecular Genetics. 15: 273-85. PMID 16330479 DOI: 10.1093/Hmg/Ddi443 |
0.337 |
|
| 2006 |
Hatton BA, Pritchard JI, Olson JM. Nervous system cancer models: Medulloblastoma Drug Discovery Today: Disease Models. 3: 167-174. DOI: 10.1016/J.Ddmod.2006.05.007 |
0.791 |
|
| 2005 |
Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, Olson JM, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9932-9. PMID 16251441 DOI: 10.1523/Jneurosci.3355-05.2005 |
0.359 |
|
| 2005 |
Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Human Molecular Genetics. 14: 3065-78. PMID 16183657 DOI: 10.1093/Hmg/Ddi340 |
0.302 |
|
| 2005 |
Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Human Molecular Genetics. 14: 1863-76. PMID 15888475 DOI: 10.1093/Hmg/Ddi192 |
0.302 |
|
| 2004 |
Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Research. 64: 7794-800. PMID 15520185 DOI: 10.1158/0008-5472.Can-04-1813 |
0.807 |
|
| 2004 |
Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends in Molecular Medicine. 10: 125-9. PMID 15102355 DOI: 10.1016/J.Molmed.2004.01.007 |
0.355 |
|
| 2004 |
Lin CH, Stoeck J, Ravanpay AC, Guillemot F, Tapscott SJ, Olson JM. Regulation of neuroD2 expression in mouse brain. Developmental Biology. 265: 234-45. PMID 14697366 DOI: 10.1016/J.Ydbio.2003.08.027 |
0.726 |
|
| 2003 |
Oh MK, Scoles DR, Haipek C, Strand AD, Gutmann DH, Olson JM, Pulst SM. Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. Journal of Cellular Biochemistry. 90: 1068-78. PMID 14624465 DOI: 10.1002/Jcb.10712 |
0.306 |
|
| 2003 |
Gilbertson RJ, Hill DA, Hernan R, Kocak M, Geyer R, Olson J, Gajjar A, Rush L, Hamilton RL, Finkelstein SD, Pollack IF. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3620-4. PMID 14506149 |
0.332 |
|
| 2003 |
Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nature Medicine. 9: 1033-8. PMID 12872164 DOI: 10.1038/Nm904 |
0.343 |
|
| 2002 |
Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (New York, N.Y.). 297: 1559-61. PMID 12202832 DOI: 10.1126/Science.1073733 |
0.478 |
|
| 2002 |
Xu XL, Olson JM, Zhao LP. A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Human Molecular Genetics. 11: 1977-85. PMID 12165559 DOI: 10.1093/Hmg/11.17.1977 |
0.302 |
|
| 2002 |
Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics. 11: 1939-51. PMID 12165556 DOI: 10.1093/Hmg/11.17.1939 |
0.329 |
|
| 2002 |
Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Human Molecular Genetics. 11: 1927-37. PMID 12165555 DOI: 10.1093/Hmg/11.17.1927 |
0.327 |
|
| 2002 |
Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Human Molecular Genetics. 11: 1911-26. PMID 12165554 DOI: 10.1093/Hmg/11.17.1911 |
0.312 |
|
| 2002 |
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415: 436-42. PMID 11807556 DOI: 10.1038/415436A |
0.32 |
|
| 2001 |
Johnston DL, Olson JM, Benjamin DR. Gastrointestinal stromal tumor in a patient with previous neuroblastoma [1] Journal of Pediatric Hematology/Oncology. 23: 255-256. PMID 11846308 DOI: 10.1097/00043426-200105000-00017 |
0.396 |
|
| 2001 |
Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S. Altered transcription in yeast expressing expanded polyglutamine Proceedings of the National Academy of Sciences of the United States of America. 98: 13201-13206. PMID 11687606 DOI: 10.1073/Pnas.191498198 |
0.307 |
|
| 2001 |
Olson JM, Asakura A, Snider L, Hawkes R, Strand A, Stoeck J, Hallahan A, Pritchard J, Tapscott SJ. NeuroD2 is necessary for development and survival of central nervous system neurons Developmental Biology. 234: 174-187. PMID 11356028 DOI: 10.1006/Dbio.2001.0245 |
0.353 |
|
| 2000 |
Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, ... Olson JM, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Molecular Genetics. 9: 1259-71. PMID 10814708 DOI: 10.1093/Hmg/9.9.1259 |
0.342 |
|
| 1997 |
Rostomily RC, Berger MS, Bermingham-McDonogh O, Olson J, Winn HR, Tapscott S. The Expression of Neurogenic Genes in Primitive Neuroectodermal Tumors (PNETs) Neurosurgery. 41: 734-734. DOI: 10.1097/00006123-199709000-00110 |
0.397 |
|
| 1994 |
Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proceedings of the National Academy of Sciences of the United States of America. 91: 8185-9. PMID 8058777 DOI: 10.1073/Pnas.91.17.8185 |
0.409 |
|
| Show low-probability matches. |